The BioPharm Brief: Fibrosis, Bispecific ADCs, and Billion-Dollar Deals

Jun 23, 10:29 PM
Headliner
Share
Subscribe

This episode explores a first-in-class antibody entering the clinic for kidney fibrosis, the world's first approved bispecific ADC, and a major acquisition that strengthens AbbVie's immunology pipeline.

Share
Subscribe
Next
The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief